Clinical Trial Update: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction [Phase 3]

View source ↗

Summary

Phase 3 study evaluating intravenous BIIB093 (glibenclamide) for severe cerebral edema after large hemispheric infarction was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Edema
• Stroke

Drugs mentioned

• BIIB093 (Glibenclamide) (glibenclamide)

Snippet

Sponsor: Remedy Pharmaceuticals, Inc. | Conditions: Brain Edema, Stroke, Acute | Phase 3 | Status: TERMINATED | Results posted: 2024-01-09